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Abstract
Background: We previously found that there is a subtle difference in the global methylation state
of blood leukocyte DNA between male subjects with and without schizophrenia. The aim of the
current study was to determine whether this difference was a primary effect of the disease state,
or a secondary effect of antipsychotics administered to these patients.
Methods: We examined the methyl cytosine (mC) content of DNA from the leukocytes, brain,
and liver of rats using high performance liquid chromatography. A total of 40 male and female rats
received for 21 days daily injection of haloperidol or vehicle solution alone.
Results: In control rats injected with buffer only, there was a sex-dependent difference in mC
content in leukocyte DNA (male > female; P = 0.028, n = 10), similar to our previous observations
in human peripheral leukocytes. No difference in mC content between the sexes was observed in
the brain or liver in buffer-treated animals. Haloperidol treatment slightly decreased the mC
content of leukocytes in male rats, but unexpectedly, increased the mC content of leukocytes in
females. We observed a trend toward a higher level of mC in the liver in both sexes following
haloperidol treatment, compared to buffer-treated animals. In contrast, haloperidol treatment
resulted in a decrease in mC content in the brain in females, and this difference was statistically
significant (P = 0.026).
Conclusion: These results indicate that haloperidol can affect DNA methylation states in the
brain, as well as in certain other tissues, and raise the possibility that antipsychotic drugs play a role
in the observed disparity in mC content in male subjects with and without schizophrenia.
Background
Epidemiological studies have established that genetic fac-
tors play a major role in the development of schizophre-
nia. However, the discordance rate for schizophrenia
between monozygotic twins is approximately 50%, sug-
gesting that epigenetic and/or environmental factors are
also involved in the development of the disease. Despite
extensive research, the molecular etiology of schizophre-
nia remains enigmatic [1,2]. The use of microarrays or
DNA chips for genome-wide analysis of gene expression is
showing that the underlying variation in gene expression
among individuals may contribute to the development of
complex traits and characteristics [3,4]. Epigenetic modi-
fications, such as DNA methylation, play an important
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role in the regulation of gene expression, primarily
through their role in regulating chromatin structure and
function [5]. Defects in epigenetic factors are linked to
several diseases [6,7]. For example, Rett syndrome, a neu-
rodevelopmental disorder, is caused by mutations in the
gene encoding methyl-CpG-binding protein-2 (MECP2)
[8], and alpha-thalassemia/mental retardation X-linked
(ATRX) syndrome is caused by mutations in ATRX, which
encodes a member of the SWI/SNF family of chromatin
remodeling proteins. Patients with ATRX syndrome
exhibit severe mental retardation as well as alpha-tha-
lassemia [9].
Unlike Rett and ATRX syndromes, symptoms of schizo-
phrenia appear later in life, suggesting that environmental
factors contribute to the development of the disease. The
methylation state of the genome undergoes highly
dynamic changes, extensive demethylation and recon-
struction during early embryogenesis, yet once estab-
lished, is very stable [10]. Nevertheless, some epigenetic
signals, including DNA methylation, can be transmitted
from one generation to the next, and are influenced by
environmental or intrinsic biological factors [11-14].
Thus, DNA methylation and/or other epigenetic modifi-
cations of the genome may help explain the ambiguity of
inherited schizophrenia and the role, if any, of environ-
mental factors in the etiology of the disease.
In developing a model of schizophrenia [15], we exam-
ined global methylation of peripheral leukocyte DNA
from more than 200 patients with schizophrenia, and
compared it to global methylation in healthy subjects.
The results revealed lower mC content in male patients
than in male controls, although the difference did not
reach a statistically significance [16]. In the present study,
we were interested in determining whether this difference
was a secondary effect of anti-psychotic medications.
Methods
Animals and chemical
Eight-week-old male and female Sprague-Dawley rats
(330 – 360 g and 190 – 230 g, respectively) were pur-
chased from Kyudo Co., Ltd. (Kumamoto, Japan), housed
in standard cages in a controlled environment at a con-
stant room temperature (24 ± 2°C) and humidity (50–
70%), and maintained on a 12 h light-dark cycle. Food
and water were provided ad libitum through out the exper-
iment. Haloperidol was kindly provided by Dainippon
Sumitomo Pharma Co., Ltd. (Osaka, Japan). The bulk
powdered chemical was dissolved in 0.1 M glacial acetic
acid buffered to pH6.0 with NaOH at concentration of
0.25 mg/ml [17]. All animal experiments were reviewed
and approved by the Ryukyu University Animal Welfare
Committee.
Experimental procedure
Ten male and 10 female rats were administered 0.5 mg/kg
haloperidol intraperitoneally on a daily basis [18]. Con-
trol rats received the same volume of vehicle solution
alone under parallel conditions. After 21 days of daily
injection, the rats were sacrificed by injection of sodium
pentobarbital (120 mg/kg) intraperitoneally. Trunk blood
was collected using a heparinized syringe, and plasma was
prepared by centrifugation at 2,000 rpm for 10 min, then
stored at -30°C until use. Layered cells, which include
whole white blood cells, following centrifugation were
isolated and set aside for DNA extraction. Whole brains,
excluding the cerebellum and olfactory bulb, liver, and
kidney were rapidly excised, rinsed twice in saline, then
snap-frozen in liquid nitrogen.
HPLC analysis
mC content in blood leukocyte DNA was evaluated using
high performance liquid chromatography (HPLC). All
reagents and conditions for HPLC analysis have been
described previously [19]. Global methylation levels are
expressed as the ratio of mC to the sum of 2'-deoxycyti-
dine and mC (%).
Statistical analysis
Statistical analyses were performed using Stat View soft-
ware (SAS Institute Inc., Cary, NC, USA). Differences in
mean mC content between the two groups were evaluated
with the Mann-Whitney U test. Results were considered
statistically significant when the P  value was less than
0.05.
Results
Physiological state of haloperidol-treated rats
All rats treated with haloperidol grew as well as control
rats and did not exhibit noticeable abnormal behavior
during the course of the experiment. Body weights and
blood concentrations of haloperidol and prolactin at the
time the animals were sacrificed are summarized in Table
1.
Sex- and tissue- specific global methylation levels in 
control rats
In a previous study, we found a sex-dependent difference
in the mC content of human leukocyte DNA, with the
level in males being greater than that in females [16,19].
In the current study, we first compared the mC content of
leukocyte DNA in male and female control rats. There was
a statistically significant difference in the mC content of
leukocyte DNA (males greater than females), which was
consistent with our previous results in humans. However,
there was no difference in the mC content between males
and females in either the brain or liver DNA (Table 2). The
differences in global methylation levels among differentBehavioral and Brain Functions 2006, 2:37 http://www.behavioralandbrainfunctions.com/content/2/1/37
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tissues were quite remarkable (leukocytes > brains > liv-
ers).
Effect of haloperidol on global methylation levels in 
leukocytes, brain, and liver
We next compared the mC content in haloperidol-
injected rats (drug group) to buffer treated control ani-
mals (control group) by sex and tissue type. In males, the
mean level of mC content of leukocyte DNA was slightly
lower in the drug group than in the control group, but the
difference was not statistically significant. In contrast, in
female leukocytes, we observed a trend toward higher mC
levels in the drug group compared to the control group,
although again, the difference did not reach a statistically
significant level (P = 0.064). Thus, the sex-dependent dif-
ference in mC content of leukocyte DNA between male
and female rats appeared to be ameliorated by haloperi-
dol treatment. Global methylation in the brains of
haloperidol-treated rats was lower than in the brains of
female control animals, and this difference was statisti-
cally significant (P = 0.026). There was a higher level of
methylation of liver DNA in the drug group compared to
the control group, for both males and females, and in
males, this difference was statistically significant (P  =
0.013). These results are summarized in Table 3. No sta-
tistically significant correlation between prolactin concen-
tration and mC content in any tissue was detected
(Spearman's ρ = -0.104, p = 0.570 in leukocytes; ρ = -
0.220, p = 0.205 in the liver; ρ = -0.193, p = 0.279 in the
brain).
Discussion
The aim of the current study was to determine whether
global hypomethylation of peripheral leukocyte DNA in
male patients with schizophrenia was a secondary effect
of their medication. As a model system for studying this
question, we chose haloperidol-injected rats, since
haloperidol, until recently, was a commonly used drug for
the treatment of schizophrenia. In leukocyte DNA from
control rats that were injected with buffer alone, there was
a sex-dependent difference in mC content (females lower
than males), similar to what was previously observed in
humans [16,19] The apparent paradox of a lower methyl-
ation state in females may be partly attributed to global
hypomethylation of the inactive X chromosome [20]. The
global methylation level in rat liver and brain was also
consistent with what has been observed in humans: liver
< brain [19]. Thus, the data obtained from rats and
humans are comparable. In male rats injected with
haloperidol, the amount of mC in leukocyte DNA was less
than that seen in control male rats, but the difference was
not statistically significant. Although further study is
needed in order to fully understand the difference in mC
content of peripheral leukocyte DNA between male
patients with schizophrenia and healthy male subjects,
the results of the current study present several interesting
Table 2: Tissue- and sex-specificity of methylcytosine (mC) content (%) in control rats
mC content in leukocyte, brain, and liver DNA (mean ± SD)
Sex (n) Leukocytes P Brain P Liver P
Male (10) 3.843 ± 0.042 0.028 3.650 ± 0.023 0.791 3.412 ± 0.033 0.496
Female (10) 3.771 ± 0.048 3.652 ± 0.031 3.426 ± 0.027
n: numbers of rats analyzed.
Differences in mean mC content between male and female rats were evaluated with the Mann-Whitney U test.
Table 1: Body weight and plasma concentrations of prolactin and haloperidol for control and haloperidol-treated rats
Sex Treatmenta Body weight (g) at Plasma concentrations of
beginning end prolactin (ng/ml) haloperidol (ng/ml)
Male haloperidol 351.5 ± 6.9 476.0 ± 8.4 64.7 ± 43.7 4.3 ± 0.9b
placebo 342.5 ± 6.3 473.0 ± 9.5 37.3 ± 10.0b 1.5, 2.0, <1.3c
Female haloperidol 211.0 ± 15.2 298.0 ± 16.9 441.1 ± 243.3 ND
placebo 211.0 ± 12.9 300.0 ± 15.6 150.5 ± 112.7b ND
aEach group consisted of 10 rats.
bn = 5
cHaloperidol was below the detection limit in three of the five rats examined.
ND: not determined due to a high background activity of unknown origin.
Plasma concentrations of prolactin and haloperidol were determined by the [125I]-labelled radioimmunoassay and colloidal gold immunoassay, 
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and novel findings, and implicate a role for haloperidol,
and perhaps other antipsychotic medications, in the alter-
ation of DNA methylation in schizophrenic male patients.
Haloperidol-treatment resulted in a decrease in the
amount of mC in leukocyte DNA in male rats, although
the difference did not reach a statistical significance. In
contrast, we found a trend toward higher levels of mC in
leukocyte DNA in female rats treated with haloperidol (P
= 0.064). Although the reasons why haloperidol treat-
ment would have opposite effects on global methylation
in male and female rats are not clear from this study, it is
possible that these differences are the result of disruptions
in the balance of hormones in these animals. This is sup-
ported by observations that there are sex-dependent dif-
ferences in the immune response to certain hormones,
and in the frequency of occurrence of some autoimmune
diseases [21-23]. It is also possible that the observed effect
might be mediated by the alteration in the subset profile
of white blood cells. The partial discrepancy between the
results obtained from patients with schizophrenia and
from rats injected with haloperidol will require additional
study, in particular into the differences between humans
and rodents in the regulation of epigenetic factors, or
other systems that may effect the course of disease
[24,25].
In the liver, haloperidol increased global DNA methyla-
tion in both males and females, and the difference was
statistically significant in males (P = 0.013). In the brain,
haloperidol treatment resulted in a decrease in females,
and the decrease was statistically significant (P = 0.026).
The differential effect of haloperidol on DNA methylation
in various tissues suggests that the regulation of global
DNA methylation by this drug occurs through multiple,
indirect pathways. In these pathways, sex-specific hor-
mones may play a role in modifying the methylation state
of DNA, since haloperidol also disturbs the normal regu-
lation of sex-hormone secretion.
Several studies have established that there are gender dif-
ferences among patients with psychiatric disorders, sug-
gesting that sex-specific hormones play a role in the
pathogenesis of these disorders, including schizophrenia
[26-29]. It remains a topic of considerable interest
whether and how these hormones are involved in disease
progression. Clinical phenotypes are most frequently the
manifestation of multiple alterations in genetic and envi-
ronmental factors. In the current study, using a limited
number of rats, we were unable to demonstrate a causa-
tive effect of haloperidol on the observed hypomethyla-
tion of leukocyte DNA in male patients with
schizophrenia [16]. However, we did uncover several sex-
and tissue-specific effects of haloperidol on DNA methyl-
ation. Of note, valproate, a drug that is commonly used to
treat bipolar disorder, has been shown to have a demeth-
ylating effect [30]. Clarification of the cellular pathways
that mediate haloperidol's effect on DNA methylation
state will help elucidate the molecular etiologies of schiz-
ophrenia.
Conclusion
In the current study, using a limited number of rats, we
were unable to demonstrate a causative effect of haloperi-
dol on the observed hypomethylation of leukocyte DNA
in male patients with schizophrenia. However, we did
uncover several sex- and tissue-specific effects of haloperi-
dol on DNA methylation, which helps the researchers
interpret the data in epigenetic studies in schizophrenia,
and also would shed light on the mechanism of action of
antipsychotics.
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Table 3: Effects of haloperidol on the mC content of leukocyte, brain, and liver DNA
mC content (mean ± SD)
Sex Treatmenta Leukocytes P Brain P Liver P
Male Haloperidol 3.817 ± 0.036 0.212 3.632 ± 0.047 0.273 3.445 ± 0.027 0.013
Placebob 3.843 ± 0.042 3.650 ± 0.023 3.412 ± 0.033
Female Haloperidol 3.812 ± 0.050 0.064 3.615 ± 0.031 0.026 3.449 ± 0.055 0.089
Placebob 3.771 ± 0.048 3.652 ± 0.031 3.426 ± 0.027
aEach treatment-group consisted of 10 rats.
binjected with solvent, NaOH-buffered acetic acid (pH6.0), alone.
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